Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials-MedSci.cn

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

Bingham, C; Jia, BC; Wu, JM; Quebe, A; Kannowski, C; Otawa, S; Chen, YF; Griffing, K; He, DY; Sholter, D